Effect of auranofin dose regimen change upon cell-associated gold in rheumatoid arthritic patients.
We examined whether changes in auranofin dose regimen in rheumatoid arthritis (RA) patients affect cell-associated and/or serum gold levels. In 7 RA patients, a reduction in daily dosage of auranofin from 3 mg bid to 3 mg qd was correlated with a marked reduction (81%-95%) in cell-associated gold, whereas a return to the 3 mg bid dose level resulted in a reinstatement of cell-associated gold. These changes in cell-associated gold were not reflected in alterations of serum gold levels. This apparent lack of change in serum gold level as opposed to cell-associated gold suggests that this phenomenon warrants further investigation.
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D001310:Auranofin; D006051:Aurothioglucose / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D006046:Gold / Q000031:analogs & derivatives* / Q000097:blood / Q000378:metabolism; D006801:Humans; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D006051:Aurothioglucose; D001310:Auranofin; D006046:Gold